Can-Fite BioPharma (CANF) 6-K 29 Aug 24 Report of Foreign Private Issuer Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2024
Document Information Line Items
Entity Registrant Name	CAN-FITE BIOPHARMA LTD.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001536196
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 4,719	$ 4,278
Short term deposits		4,625
Prepaid expenses and other current assets	1,100	986
Short-term investment	9	19
Total current assets	5,828	9,908
NON-CURRENT ASSETS:
Operating lease right of use assets	62	52
Property, plant and equipment, net	32	29
Total non-current assets	94	81
Total assets	5,922	9,989
CURRENT LIABILITIES:
Trade payables	885	427
Current maturity of operating lease liability	36	27
Deferred revenues	636	622
Other accounts payable	430	944
Total current liabilities	1,987	2,020
NON-CURRENT LIABILITIES:
Operating lease liability	21	13
Deferred revenues	1,435	1,713
Total long-term liabilities	1,456	1,726
CONTINGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS’ EQUITY:
Ordinary shares of no-par value - Authorized: 5,000,000,000 shares at June 30, 2024 and December 31, 2023; Issued and outstanding: 1,671,728,493 and 1,359,837,393 shares as of June 30, 2024 and December 31, 2023, respectively
Additional paid-in capital	163,790	163,597
Accumulated other comprehensive income	1,127	1,127
Accumulated deficit	(162,438)	(158,481)
Total shareholders’ equity	2,479	6,243
Total liabilities and shareholders’ equity	$ 5,922	$ 9,989

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Ordinary shares, par value (in Dollars per share)
Ordinary shares, shares authorized	5,000,000,000	5,000,000,000
Ordinary shares, shares issued	1,671,728,493	1,359,837,393
Ordinary shares, shares outstanding	1,671,728,493	1,359,837,393

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenues		$ 316	$ 392
Research and development expenses		(2,885)	(3,417)
General and administrative expenses		(1,525)	(1,471)
Operating loss		(4,094)	(4,496)
Financial income, net		137	276
Comprehensive loss		$ (3,957)	$ (4,220)
Basic net loss per share (in Dollars per share)		$ 0	$ 0
Weighted average number of ordinary shares used in computing basic net loss per share (in Shares)	[1]	1,821,304,184	1,202,110,110
[1]Including ordinary shares held in abeyance.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Diluted net loss per share		$ 0	$ 0
Weighted average number of ordinary shares used in computing diluted net loss per share	[1]	1,821,304,184	1,202,110,110
[1]Including ordinary shares held in abeyance.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes In Equity (Unaudited) - USD ($) $ in Thousands	Ordinary shares	Additional paid-in capital	Accumulated other comprehensive Income	Accumulated deficit	Total
Balance at Dec. 31, 2022		$ 154,192	$ 1,127	$ (150,847)	$ 4,472
Balance (in Shares) at Dec. 31, 2022	815,746,293
Comprehensive loss				(4,220)	(4,220)
Issuance of ordinary shares and warrants, net of issuance costs of $ 978		6,526			6,526
Issuance of ordinary shares and warrants, net of issuance costs of $ 978 (in Shares)	90,000,000
Issuance of ordinary shares due to exercise of pre-funded warrants		1			1
Issuance of ordinary shares due to exercise of pre-funded warrants (in Shares)	319,091,100
Share-based payments		95			95
Balance at Jun. 30, 2023		160,814	1,127	(155,067)	6,874
Balance (in Shares) at Jun. 30, 2023	1,224,837,393
Balance at Dec. 31, 2023		163,597	1,127	(158,481)	$ 6,243
Balance (in Shares) at Dec. 31, 2023	1,359,837,393				1,359,837,393
Comprehensive loss				(3,957)	$ (3,957)
Release of ordinary shares that were previously held in abeyance (refer to note 4)
Release of ordinary shares that were previously held in abeyance (refer to note 4) (in Shares)	296,891,100				296,891,100
Share-based payments		193			$ 193
Share-based payments (in Shares)	15,000,000
Balance at Jun. 30, 2024		$ 163,790	$ 1,127	$ (162,438)	$ 2,479
Balance (in Shares) at Jun. 30, 2024	1,671,728,493				1,671,728,493

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes In Equity (Unaudited) (Parentheticals) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Statement of Stockholders' Equity [Abstract]
Net of issuance costs	$ 978

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (3,957)	$ (4,220)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant and equipment	1	8
Reduction in the carrying amount of operating lease right of use asset	23	28
Share-based payments	193	95
Changes in fair value of short-term investment	10	(3)
Financial expenses (income), net	144	(146)
Change in prepaid expenses, and other current assets	(114)	(123)
Decrease in operating lease liability	(16)	(27)
Increase (decrease) in trade payables	458	(86)
Decrease in deferred revenues	(264)	(392)
Decrease in other accounts payable	(514)	(179)
Net cash used in operating activities	(4,036)	(5,045)
Cash flows from investing activities:
Purchase of property, plant and equipment	(4)	(2)
Maturity (investment) in short term deposits, net	4,500	(1,000)
Net cash used in investing activities	4,496	(1,002)
Cash flows from financing activities:
Proceeds from issuance of ordinary shares and warrants, net of issuance costs		6,526
Proceeds from issuance of ordinary share due to exercise of pre-funded warrants		1
Net cash provided by financing activities		6,527
Exchange differences on balances of cash and cash equivalents	(19)		[1]
Increase in cash and cash equivalents	441	480
Cash and cash equivalents at the beginning of the period	4,278	2,978
Cash and cash equivalents at the end of the period	4,719	3,458
Supplemental disclosures of noncash investing and financing activities:
Lease liabilities arising from obtaining right-of-use-assets	$ 14	$ 32
[1]Represent an amount of lower than $1.

General

General	6 Months Ended
	Jun. 30, 2024
General [Abstract]
GENERAL	NOTE 1:- GENERAL a. Can-Fite Biopharma Ltd. (the “Company”) was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, NASH and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. The Company’s pipeline of drug candidates are synthetic, highly specific agonists and allosteric modulators at the A3AR. The Company’s ordinary shares have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol “CFBI” and the Company’s American Depositary Shares (“ADSs”) began public trading on the over the counter market in the U.S. in October 2012 and since November 2013 the Company’s ADSs have been publicly traded on the NYSE American under the symbol “CANF”. Each ADS represents 300 ordinary shares of the Company. b. Under Accounting Standard Codification (“ASC”) Subtopic 205-40, Presentation of Financial Statements—Going Concern (“ASC 205-40”), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its obligations as they become due within one year after the date that the financial statements are issued. As required under ASC 205-40, management’s evaluation should initially not take into consideration the potential mitigating effects of management’s plans that have not been fully implemented as of the date the financial statements are issued. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Evaluation of Substantial Doubt Raised In performing the first step of the evaluation, the Company concluded that the following conditions raised substantial doubt about its ability to continue as a going concern: ● History of net losses of $3,957 and $4,220 for the six months ended June 30, 2024 and 2023, respectively. ● Net operating cash outflow of $4,036 and $5,045 for the six months ended June 30, 2024 and 2023, respectively. ● Reliance on additional financing in order to execute its research and development plans. Consideration of Management’s Plans In performing the second step of this assessment, the Company is required to evaluate whether it is probable that the Company’s plans will be effectively implemented within one year after the financial statements are issued and whether it is probable those plans will alleviate the substantial doubt raised about the Company’s ability to continue as a going concern. As of June 30, 2024, the Company had $4,719 in available cash and cash equivalents. The Company is prepared to implement the following actions as required by business and market conditions: reducing non-essential expenses to conserve cash and improve its liquidity position, deferral and reprioritization of certain research and development programs that would involve reduced program spend until additional financing will be obtained in order to strengthen liquidity and to preserve key research and development, commercial and functional roles. On August 8, 2024, subsequent to the balance sheet date, the Company entered into an inducement letter with an existing investor, according to which 857,142,900 warrants were exercised to ordinary shares for total consideration of $4,474 net of issuance costs. Refer to note 5 for additional information. Management Assessment of Ability to Continue as a Going Concern The Company has a history of operating losses and negative cash flows from operations. However, despite these conditions, the Company believes management’s plans, as described more fully above, will provide sufficient liquidity to meet its financial obligations. Therefore, management concluded these plans alleviate the substantial doubt that was raised about the Company’s ability to continue as a going concern for at least twelve months from the date that the consolidated financial statements were issued. Future Plans and Considerations Although not considered for purposes of the Company’s assessment of whether substantial doubt was alleviated, the Company has plans to improve operating cash flows by entering into strategic partnerships with other companies that can provide access to additional customers and new markets. The Company may also seek to raise additional funds through the issuance of debt and/or equity securities or otherwise. The Company’s plans are subject to inherent risks and uncertainties. Accordingly, there can be no assurance that the Company’s plans can be effectively implemented and, therefore, that the conditions can be effectively mitigated. Until such time, if ever, that the Company can generate revenue sufficient to achieve profitability, the Company expects to finance its operations through equity or debt financings, which may not be available to the Company on the timing needed or on terms that the Company deems to be favorable. To the extent that the Company raises additional capital through the sale of equity or debt securities, the ownership interest of its stockholders will be diluted. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. c. Basis of Presentation: These unaudited Condensed consolidated financial statements have been prepared as of June 30, 2024 and for the six months period then ended. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. These unaudited Condensed consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes of the Company for the year ended December 31, 2023 that are included in the Company’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 28, 2024 (the “Annual Report on Form 20-F”). The results of operations presented are not necessarily indicative of the results to be expected for the year ending December 31, 2024. The significant accounting policies that have been applied in the preparation of the unaudited consolidated Condensed financial statements are identical to those that were applied in preparation of the Company’s most recent annual financial statements for the year ended December 31, 2023 included in the Annual Report on Form 20-F. d. Revenue Recognition – Contract Balances Contract liabilities include amounts received from customers for which revenue has not yet been recognized. Contract liabilities amounted to $2,071 and $2,335 as of June 30, 2024 and December 31, 2023, respectively and are presented under deferred revenues. During the six-month period ended June 30, 2024, the Company recognized revenues in the amount of $316 which have been included in the contract liabilities at December 31, 2023.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Fair Value Measurements [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 2:- FAIR VALUE MEASUREMENTS In accordance with ASC 820 “Fair Value Measurements and Disclosures”, the Company measures its short-term investment at fair value. Short-term investments are classified within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. The company’s short-term investment consists of an equity investment in a publicly traded company. The Company’s financial assets and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates: instruments as of the following dates: June 30, 2024 Fair value measurements Description Fair value Level 1 Level 2 Level 3 Short-term investment $ 9 $ 9 $ - $ - December 31, 2023 Fair value measurements Description Fair value Level 1 Level 2 Level 3 Short-term investment $ 19 $ 19 $ - $ -

Earning Per Share

Earning Per Share	6 Months Ended
	Jun. 30, 2024
Earning Per Share [Abstract]
EARNING PER SHARE	NOTE 3:- EARNING PER SHARE Basic and diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each period. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, “Earnings per Share”. The following table sets forth the computation of basic and diluted net loss per share for the periods presented: Six month ended June 30, 2024 2023 Numerator: Net loss applicable to shareholders of Ordinary Shares $ (3,957 ) $ (4,220 ) Denominator: Weighted average shares used in computing basic and diluted net loss per share *) 1,821,304,184 1,202,110,110 Net loss per share of Ordinary Share, basic and diluted $ (0.00 ) $ (0.00 ) *) Including ordinary shares held in abeyance. All outstanding share options and warrants (except for prefunded warrants) for the period ended June 30, 2024 and 2023 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. The potential shares of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows: Six month ended 2024 2023 Options 86,064,500 42,477,000 Warrants 1,851,518,298 1,222,016,340 Total 1,937,582,798 1,264,493,340

Contingent Liabilities and Comm

Contingent Liabilities and Commitments	6 Months Ended
	Jun. 30, 2024
Contingent Liabilities and Commitments [Abstract]
CONTINGENT LIABILITIES AND COMMITMENTS	NOTE 4:- CONTINGENT LIABILITIES AND COMMITMENTS According to the patent license agreement that the Company entered into with Leiden University in the Netherlands on November 2, 2009, which is affiliated with the National Institutes of Health (NIH), the Company was granted an exclusive license for the use of the patents of several compounds, including CF602 in certain territories. The Company is committed to pay royalties as follows: a. A one-time concession commission of €25 thousand; b. Annual royalties of €10 thousand until the clinical trials commence; c. 2%-3% of net sales (as defined in the agreement) received by the Company; d. Royalties in a total amount of up to €850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) €50 thousand upon initiation of Phase I studies; (ii) €100 thousand upon initiation of Phase II studies; (iii) €200 thousand upon initiation of Phase III studies; and (iv) €500 thousand upon marketing approval by any regulatory authority. e. If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of 10%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph.

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2024
Shareholders Equity [Abstract]
SHAREHOLDERS’ EQUITY	NOTE 5:- SHAREHOLDERS’ EQUITY As of June 30, 2024 and December 31, 2023, no material accrual has been recorded with respect to Leiden University. a. All ordinary shares have equal rights for all intent and purposes and each ordinary share confers its holder: 1. The right to be invited and participate in all the Company’s general meetings, both annual and regular, and the right to one vote per ordinary share owned in all votes and in all Company’s general meeting participated. 2. The right to receive dividends if and when declared and the right to receive bonus shares if and when distributed. 3. The right to participate in the distribution of the Company’s assets upon liquidation. b. During the six months period ended June 30, 2024, the Company issued 296,891,100 ordinary shares previously held in abeyance. As of June 30, 2024, 157,200,000 ordinary shares held in abeyance. c. On April 1, 2024 the Company issued 15,000,000 ordinary shares to certain service provider in exchange for PR services. The shares issued were valued at the amount of $112 which were recorded to general and administrative expenses during the six months ended June 30, 2024. d. Share options plan: On November 28, 2013, the board of directors approved the adoption of the 2013 Share Option Plan (the “2013 Plan”). Under the Company’s 2013 Plan, in May 2023, the Company’s Board of Directors approved to increase number of ordinary shares reserved for issuance to 85,000,000. On August 30, 2023, the Company’s board of directors approved the adoption on a new 2023 Share Option Plan (the “2023 Plan”) and approved the reserve of 100,000,000 of the Company’s ordinary shares to issuance under the 2023 Plan. As of June 30, 2024, 91,000,000 shares available for future grant under the Company’s 2023 Plans. On May 7, 2024, the Company’s board of directors approved a grant of 9,000,000 options exercisable into 9,000,000 of the Company’s ordinary shares to the Company’s employees for an exercise price of NIS 0.0275 per share and 41,000,000 unlisted options exercisable into 41,000,000 of the Company’s ordinary shares to the Company’s directors and officers (subject to shareholders’ approval, which was obtained on July 3, 2024, subsequent to the balance sheet date) for the same exercise price per share. The options shall vest on a quarterly basis for a period of 4 years from the date of grant. The fair value of the Company’s share options granted was estimated using the binomial option pricing model using the following range assumptions: Description May 7, Risk-free interest rate 4.64 % Expected volatility 83.40 % Dividend yield 0 % Contractual life (in years) 10 Early Exercise Multiple (Suboptimal Factor) 2.5 The following table lists the number of share options and their weighted average exercise prices in option plans of employees, directors and consultants for the six months period ended June 30, 2024 and related information: Number of options Weighted Weighted Aggregate Outstanding at December 31, 2023 82,477,000 0.04 8.40 - Grants 9,000,000 0.00 9.85 - Forfeited/expired (5,412,500 ) - - - Outstanding at June 30, 2024 86,064,500 0.04 5.6 0.04 Vested and expected to vest at June 30, 2024 86,064,500 0.04 5.6 0.04 Exercisable at June 30, 2024 33,998,875 0.08 5.4 - Share based expenses recognized in the financial statements: Six months ended 2024 2023 Research and development $ 34 $ 50 General and administrative (*) 159 45 $ 193 $ 95 (*) Including expenses for shares issued for services at the amount of $112, refer to Note 4c above. a. Warrants to purchase ordinary shares: The following table summarizes information regarding outstanding warrants to purchase the Company’s ordinary shares as of June 30, 2024: Issuance date Number of Exercise January 2019 223,810 $ 0.65 May 2019 47,250,000 $ 0.13 January 2020 23,838,038 $ 0.12 February 2020 11,250,000 $ 0.05 June 2020 61,390,260 $ 0.08 July 2020 29,419,890 $ 0.08 August 2021 10,500,000 $ 0.07 December 2021 10,500,000 $ 0.07 January 2023 409,091,100 $ 0.01 January 2023 28,636,500 $ 0.02 November 2023 1,219,418,700 $ 0.00 1,851,518,298

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 6:- SUBSEQUENT EVENTS a. On July 3, 2024, the Company’s shareholders meeting approved the increase of the Company’s authorized share capital by an additional 5,000,000,000 ordinary shares such that following the increase, the authorized share capital shall be 10,000,000,000 ordinary shares. b. On August 8, 2024, the Company entered into an inducement offer letter with a certain existing warrants holder, according to which, the holder exercised warrants exercisable for an aggregate of 857,142,900 ordinary shares (represented by 2,857,143 ADSs) for an exercise price of $0.00583 per share (or $1.75 per ADS), totaling $5 million in gross consideration. As part of the inducement letter, the Company issued to the holder new warrants to purchase 1,714,285,800 of the Company’s ordinary shares (represented by 5,714,286 ADSs) for an exercise price of $0.0075 per share (or $2.25 per ADS). The Company also issued to its placement agent new warrants exercisable into 60,000,000 ordinary shares (represented by 200,000 ADSs) at an exercise price of $0.00729167 per share or ($2.1875 per ADS).

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation:	c. Basis of Presentation: These unaudited Condensed consolidated financial statements have been prepared as of June 30, 2024 and for the six months period then ended. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. These unaudited Condensed consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes of the Company for the year ended December 31, 2023 that are included in the Company’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 28, 2024 (the “Annual Report on Form 20-F”). The results of operations presented are not necessarily indicative of the results to be expected for the year ending December 31, 2024. The significant accounting policies that have been applied in the preparation of the unaudited consolidated Condensed financial statements are identical to those that were applied in preparation of the Company’s most recent annual financial statements for the year ended December 31, 2023 included in the Annual Report on Form 20-F.
Revenue Recognition – Contract Balances	d. Revenue Recognition – Contract Balances Contract liabilities include amounts received from customers for which revenue has not yet been recognized. Contract liabilities amounted to $2,071 and $2,335 as of June 30, 2024 and December 31, 2023, respectively and are presented under deferred revenues. During the six-month period ended June 30, 2024, the Company recognized revenues in the amount of $316 which have been included in the contract liabilities at December 31, 2023.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Measurements [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis	The Company’s financial assets and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates: instruments as of the following dates: June 30, 2024 Fair value measurements Description Fair value Level 1 Level 2 Level 3 Short-term investment $ 9 $ 9 $ - $ - December 31, 2023 Fair value measurements Description Fair value Level 1 Level 2 Level 3 Short-term investment $ 19 $ 19 $ - $ -

Earning Per Share (Tables)

Earning Per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Earning Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share for the periods presented: Six month ended June 30, 2024 2023 Numerator: Net loss applicable to shareholders of Ordinary Shares $ (3,957 ) $ (4,220 ) Denominator: Weighted average shares used in computing basic and diluted net loss per share *) 1,821,304,184 1,202,110,110 Net loss per share of Ordinary Share, basic and diluted $ (0.00 ) $ (0.00 ) *) Including ordinary shares held in abeyance.
Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders	The potential shares of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows: Six month ended 2024 2023 Options 86,064,500 42,477,000 Warrants 1,851,518,298 1,222,016,340 Total 1,937,582,798 1,264,493,340

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2024
Shareholders Equity [Abstract]
Schedule of Fair value of Company’s Share Options Granted	The fair value of the Company’s share options granted was estimated using the binomial option pricing model using the following range assumptions: Description May 7, Risk-free interest rate 4.64 % Expected volatility 83.40 % Dividend yield 0 % Contractual life (in years) 10 Early Exercise Multiple (Suboptimal Factor) 2.5
Schedule of Weighted Average Exercise Prices Share Options	The following table lists the number of share options and their weighted average exercise prices in option plans of employees, directors and consultants for the six months period ended June 30, 2024 and related information: Number of options Weighted Weighted Aggregate Outstanding at December 31, 2023 82,477,000 0.04 8.40 - Grants 9,000,000 0.00 9.85 - Forfeited/expired (5,412,500 ) - - - Outstanding at June 30, 2024 86,064,500 0.04 5.6 0.04 Vested and expected to vest at June 30, 2024 86,064,500 0.04 5.6 0.04 Exercisable at June 30, 2024 33,998,875 0.08 5.4 -
Schedule of Expenses Recognized Financial Statements	Share based expenses recognized in the financial statements: Six months ended 2024 2023 Research and development $ 34 $ 50 General and administrative (*) 159 45 $ 193 $ 95 (*) Including expenses for shares issued for services at the amount of $112, refer to Note 4c above.
Schedule of Information Regarding Outstanding Warrants to Purchase Shares	The following table summarizes information regarding outstanding warrants to purchase the Company’s ordinary shares as of June 30, 2024: Issuance date Number of Exercise January 2019 223,810 $ 0.65 May 2019 47,250,000 $ 0.13 January 2020 23,838,038 $ 0.12 February 2020 11,250,000 $ 0.05 June 2020 61,390,260 $ 0.08 July 2020 29,419,890 $ 0.08 August 2021 10,500,000 $ 0.07 December 2021 10,500,000 $ 0.07 January 2023 409,091,100 $ 0.01 January 2023 28,636,500 $ 0.02 November 2023 1,219,418,700 $ 0.00 1,851,518,298

General (Details)

General (Details) - USD ($) $ in Thousands		6 Months Ended
	Aug. 08, 2024	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
General [Abstract]
Number of ordinary shares in each ADS (in Shares)		300
Net losses		$ (3,957)	$ (4,220)
Net operating cash outflow		(4,036)	(5,045)
Cash and cash equivalents		4,719
Warrants exercised (in Shares)	857,142,900
Net of issuance costs	$ 4,474
Contract liabilities		2,071		$ 2,335
Revenue		$ 316	$ 392

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis [Line Items]
Short-term investment	$ 9	$ 19
Level 1 [Member]
Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis [Line Items]
Short-term investment	9	19
Level 2 [Member]
Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis [Line Items]
Short-term investment
Level 3 [Member]
Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis [Line Items]
Short-term investment

Earning Per Share (Details) - S

Earning Per Share (Details) - Schedule of Computation of Basic and Diluted Net Loss Per Share - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Numerator:
Net loss applicable to shareholders of Ordinary Shares		$ (3,957)	$ (4,220)
Denominator:
Weighted average shares used in computing basic net loss per share	[1]	1,821,304,184	1,202,110,110
Net loss per share of Ordinary Share, basic		$ 0	$ 0
[1]Including ordinary shares held in abeyance.

Earning Per Share (Details) -_2

Earning Per Share (Details) - Schedule of Computation of Basic and Diluted Net Loss Per Share (Parentheticals) - $ / shares		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Schedule of Computation of Basic and Diluted Net Loss Per Share [Abstract]
Weighted average shares used in computing diluted net loss per share	[1]	1,821,304,184	1,202,110,110
Net loss per share of Ordinary Share, diluted		$ 0	$ 0
[1]Including ordinary shares held in abeyance.

Earning Per Share (Details) -_3

Earning Per Share (Details) - Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders [Line Items]
Potential shares of ordinary shares	1,937,582,798	1,264,493,340
Options [Member]
Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders [Line Items]
Potential shares of ordinary shares	86,064,500	42,477,000
Warrants [Member]
Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders [Line Items]
Potential shares of ordinary shares	1,851,518,298	1,222,016,340

Contingent Liabilities and Co_2

Contingent Liabilities and Commitments (Details) € in Thousands	6 Months Ended
	Jun. 30, 2024 EUR (€)
Contingent Liabilities and Commitments [Line Items]
Commission income expense	€ 25
Annual royalties	10
Royalties amount	€ 850
Royalty payments, percentage	10%
Phase I studies [Member]
Contingent Liabilities and Commitments [Line Items]
Royalties amount	€ 50
Phase II studies [Member]
Contingent Liabilities and Commitments [Line Items]
Royalties amount	100
Phase III studies [Member]
Contingent Liabilities and Commitments [Line Items]
Royalties amount	200
Regulatory Authority [Member]
Contingent Liabilities and Commitments [Line Items]
Royalties amount	€ 500
Minimum [Member]
Contingent Liabilities and Commitments [Line Items]
Percentage of net sales	2%
Maximum [Member]
Contingent Liabilities and Commitments [Line Items]
Percentage of net sales	(3.00%)

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands					6 Months Ended
	May 07, 2024	Apr. 01, 2024	Aug. 30, 2023	Nov. 28, 2013	Jun. 30, 2024
Shareholders' Equity [Line Items]
Shares held in abeyance					296,891,100
Expenses for shares issued for services (in Dollars)					$ 112
Shares available for future grant					91,000,000
Share grant					9,000,000
Ordinary per share issued (in Dollars per share)	$ 0.0275
Options exercisable					33,998,875
Date of grant					5 years 7 months 6 days
Leiden University [Member]
Shareholders' Equity [Line Items]
Shares held in abeyance					157,200,000
Board of Directors [Member]
Shareholders' Equity [Line Items]
Increase number of ordinary shares				85,000,000
Share grant	9,000,000
Option exerisable	9,000,000
Ordinary Shares [Member]
Shareholders' Equity [Line Items]
Share-based payments shares issued		15,000,000
Expenses for shares issued for services (in Dollars)					$ 112
Increase number of ordinary shares			100,000,000
Option exerisable	41,000,000
Options exercisable	41,000,000
Date of grant	4 years

Shareholders' Equity (Details)

Shareholders' Equity (Details) - Schedule of Fair value of Company’s Share Options Granted	May 07, 2024
Schedule of Fair value of Company’s Share Options Granted [Abstract]
Risk-free interest rate	4.64%
Expected volatility	83.40%
Dividend yield	0%
Contractual life (in years)	10 years
Early Exercise Multiple (Suboptimal Factor)	2.5

Shareholders' Equity (Details_2

Shareholders' Equity (Details) - Schedule of Weighted Average Exercise Prices Share Options - $ / shares		6 Months Ended
	Dec. 31, 2023	Jun. 30, 2024
Schedule of Weighted Average Exercise Prices Share Options [Abstract]
Number of options, Grants (in Shares)		9,000,000
Weighted average exercise price, Grants		$ 0
Weighted average remaining contractual terms, Grants		9 years 10 months 6 days
Aggregate intrinsic value , Grants
Number of options, Forfeited/expired (in Shares)		(5,412,500)
Weighted average exercise price, Forfeited/expired
Aggregate intrinsic value, Forfeited/expired
Number of options, Ending (in Shares)	82,477,000	86,064,500
Weighted average exercise price, Ending	$ 0.04	$ 0.04
Weighted average remaining contractual terms, Ending	8 years 4 months 24 days	5 years 7 months 6 days
Aggregate intrinsic value, Ending		$ 0.04
Number of options, Vested and expected to vest (in Shares)		86,064,500
Weighted average exercise price, Vested and expected to vest		$ 0.04
Weighted average remaining contractual terms, Vested and expected to vest		5 years 7 months 6 days
Aggregate intrinsic value, Vested and expected to vest		$ 0.04
Number of options, Exercisable (in Shares)		33,998,875
Weighted average exercise price, Exercisable		$ 0.08
Weighted average remaining contractual terms, Exercisable		5 years 4 months 24 days
Aggregate intrinsic value, Exercisable

Shareholders' Equity (Details_3

Shareholders' Equity (Details) - Schedule of Expenses Recognized Financial Statements - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Schedule of Expenses Recognized Financial Statements [Line Items]
Share based expenses recognized		$ 193	$ 95
Research and development [Member]
Schedule of Expenses Recognized Financial Statements [Line Items]
Share based expenses recognized		34	50
General and administrative [Member]
Schedule of Expenses Recognized Financial Statements [Line Items]
Share based expenses recognized	[1]	$ 159	$ 45
[1]Including expenses for shares issued for services at the amount of $112, refer to Note 4c above.

Shareholders' Equity (Details_4

Shareholders' Equity (Details) - Schedule of Information Regarding Outstanding Warrants to Purchase Shares - Warrants [Member]	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Schedule of Information Regarding Outstanding Warrants to Purchase Shares [Line Items]
Number of outstanding warrants	1,851,518,298
January 2019 [Member]
Schedule of Information Regarding Outstanding Warrants to Purchase Shares [Line Items]
Issuance date	January 2019
Number of outstanding warrants	223,810
Exercise price per warrant (in Dollars per share) | $ / shares	$ 0.65
May 2019 [Member]
Schedule of Information Regarding Outstanding Warrants to Purchase Shares [Line Items]
Issuance date	May 2019
Number of outstanding warrants	47,250,000
Exercise price per warrant (in Dollars per share) | $ / shares	$ 0.13
January 2020 [Member]
Schedule of Information Regarding Outstanding Warrants to Purchase Shares [Line Items]
Issuance date	January 2020
Number of outstanding warrants	23,838,038
Exercise price per warrant (in Dollars per share) | $ / shares	$ 0.12
February 2020 [Member]
Schedule of Information Regarding Outstanding Warrants to Purchase Shares [Line Items]
Issuance date	February 2020
Number of outstanding warrants	11,250,000
Exercise price per warrant (in Dollars per share) | $ / shares	$ 0.05
June 2020 [Member]
Schedule of Information Regarding Outstanding Warrants to Purchase Shares [Line Items]
Issuance date	June 2020
Number of outstanding warrants	61,390,260
Exercise price per warrant (in Dollars per share) | $ / shares	$ 0.08
July 2020 [Member]
Schedule of Information Regarding Outstanding Warrants to Purchase Shares [Line Items]
Issuance date	July 2020
Number of outstanding warrants	29,419,890
Exercise price per warrant (in Dollars per share) | $ / shares	$ 0.08
August 2021 [Member]
Schedule of Information Regarding Outstanding Warrants to Purchase Shares [Line Items]
Issuance date	August 2021
Number of outstanding warrants	10,500,000
Exercise price per warrant (in Dollars per share) | $ / shares	$ 0.07
December 2021 [Member]
Schedule of Information Regarding Outstanding Warrants to Purchase Shares [Line Items]
Issuance date	December 2021
Number of outstanding warrants	10,500,000
Exercise price per warrant (in Dollars per share) | $ / shares	$ 0.07
January 2023 [Member]
Schedule of Information Regarding Outstanding Warrants to Purchase Shares [Line Items]
Issuance date	January 2023
Number of outstanding warrants	409,091,100
Exercise price per warrant (in Dollars per share) | $ / shares	$ 0.01
January 2023 One [Member]
Schedule of Information Regarding Outstanding Warrants to Purchase Shares [Line Items]
Issuance date	January 2023
Number of outstanding warrants	28,636,500
Exercise price per warrant (in Dollars per share) | $ / shares	$ 0.02
November 2023 [Member]
Schedule of Information Regarding Outstanding Warrants to Purchase Shares [Line Items]
Issuance date	November 2023
Number of outstanding warrants	1,219,418,700
Exercise price per warrant (in Dollars per share) | $ / shares	$ 0

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - $ / shares	Aug. 08, 2024	Jul. 03, 2024
Subsequent Events [Line Items]
Increase in authorized ordinary shares		5,000,000,000
Exercised warrants	857,142,900
Warrant exercise price per share (in Dollars per share)	$ 0.00583
New Warrants to Purchase [Member]
Subsequent Events [Line Items]
Exercised warrants	60,000,000
Warrant exercise price per share (in Dollars per share)	$ 0.00729167
Warrant purchase	1,714,285,800
Ordinary Shares [Member]
Subsequent Events [Line Items]
Increase in authorized ordinary shares		10,000,000,000
Warrant exercise price per share (in Dollars per share)	$ 0.0075
ADR [Member]
Subsequent Events [Line Items]
Exercised warrants	2,857,143
Warrant exercise price per share (in Dollars per share)	$ 2.1875
Warrant purchase	5,714,286
ADR [Member] | New Warrants to Purchase [Member]
Subsequent Events [Line Items]
Exercised warrants	200,000
Warrant exercise price per share (in Dollars per share)	$ 1.75
Warrant [Member] | ADR [Member]
Subsequent Events [Line Items]
Warrant exercise price per share (in Dollars per share)	$ 2.25